A genetic test that uses a saliva or blood sample to predict a person's risk of cognitive decline due to Alzheimer's disease is expected to be available to doctors in the coming months.
The test, genoScore, is a collaboration between Infinity BiologiX and Cytox and can be used to assess patients before symptoms arise and prior to invasive cerebrospinal fluid testing. Additionally, the test gives patients the convenience of collecting samples at home.
